The Gene Therapy / Analysis theme has 40 member stock(s) today, with an average return of -1.8%. The leading stock is 지니너스 (+6.1%, trading value 1,607,798,697).
A precision medicine theme modifying the root causes of diseases using gene scissors, gaining attention as an innovative biopharmaceutical technology that opens possibilities for treating incurable diseases.
| Stock | Price | Return | Trading Value |
|---|---|---|---|
| 지니너스 | 1,915 | +6.1% | 1,607,798,697 |
| 지씨지놈 | 6,010 | +3.3% | 436,049,610 |
| 제놀루션 | 1,479 | +2.6% | 44,116,212 |
| CG인바이츠 | 969 | +1.7% | 96,233,570 |
| 씨젠 | 31,950 | +1.3% | 11,143,340,300 |
| 젠큐릭스 | 1,957 | +0.9% | 327,319,487 |
| 에스디바이오센서 | 6,210 | +0.8% | 566,116,135 |
| 엔젠바이오 | 1,269 | +0.5% | 208,901,152 |
| 테라젠이텍스 | 2,135 | +0.5% | 80,671,390 |
| 랩지노믹스 | 500 | 0.0% | 0 |
| 엑세스바이오 | 2,470 | -0.2% | 241,902,105 |
| CJ 바이오사이언스 | 3,835 | -0.5% | 13,486,390 |
| 엑셀세라퓨틱스 | 1,007 | -0.9% | 62,113,971 |
| 신라젠 | 2,210 | -0.9% | 1,129,915,199 |
| 신테카바이오 | 1,226 | -1.1% | 110,561,080 |
| 진시스템 | 4,200 | -1.2% | 26,539,440 |
| 앱클론 | 20,250 | -1.2% | 1,457,022,545 |
| 아이엠비디엑스 | 2,710 | -1.3% | 40,237,175 |
| 녹십자 | 126,600 | -1.3% | 1,925,362,350 |
| HLB파나진 | 1,156 | -1.5% | 30,990,075 |
| 제넥신 | 2,790 | -1.6% | 313,245,410 |
| 지노믹트리 | 10,080 | -1.7% | 517,822,000 |
| 마크로젠 | 11,800 | -1.7% | 108,878,780 |
| 코오롱생명과학 | 14,090 | -2.0% | 444,036,820 |
| 소마젠 | 3,150 | -2.2% | 349,234,410 |
| 지놈앤컴퍼니 | 3,175 | -2.3% | 287,924,905 |
| 고바이오랩 | 2,770 | -2.5% | 44,712,235 |
| HLB제넥스 | 1,760 | -2.6% | 127,430,425 |
| 알지노믹스 | 25,650 | -3.2% | 4,655,868,775 |
| 헬릭스미스 | 2,920 | -3.6% | 262,389,380 |
| 큐로셀 | 22,000 | -3.7% | 743,471,525 |
| 티움바이오 | 4,480 | -3.8% | 297,039,650 |
| 제이에스링크 | 30,100 | -4.3% | 2,868,253,050 |
| 쓰리빌리언 | 4,105 | -4.5% | 558,017,330 |
| 바이오니아 | 9,500 | -4.7% | 5,775,355,200 |
| 바이젠셀 | 6,220 | -4.9% | 673,240,545 |
| 이엔셀 | 5,150 | -5.2% | 133,940,080 |
| 툴젠 | 30,400 | -6.5% | 2,047,850,800 |
| 셀레믹스 | 12,790 | -7.3% | 760,910,175 |
| 아미코젠 | 822 | -12.0% | 1,025,042,150 |
This page's data is for reference only and is not investment advice. Actual market data may differ.